NFKB1 and osteosarcoma: Numerous studies have shown that pristimerin inhibits PI3K/AKT pathway evidenced by the dephosphorylation of Akt and its downstream factors such as mTOR, FoxO3a, and NF−κB in UM (18), OSCC (27), breast cancer (32, 50), pancreatic cancer (60), ovarian cancer (57), osteosarcoma (70), and fibrosarcoma (66).